Lung Cancer |

Prognostic Value of C-kit and VEGF Expression in Small Cell Lung Cancer FREE TO VIEW

Gulen Topaloglu, MD; Aydin Yilmaz, MD; Funda Demirag, MD; Yurdanur Erdogan, MD; Sezgi Sahin Duyar, MD; Ulkü Yilmaz, MD
Author and Funding Information

Kayseri Education and Research Hospital, Kayseri, Turkey

Chest. 2015;148(4_MeetingAbstracts):592A. doi:10.1378/chest.2251317
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Treatment Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: Lung cancer is the leading cause of cancer related death in the world. Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor clinical course. Despite using new technologies and chemotherapeutic agents, little progress has been made in prolonging survival in SCLC. Performans status (PS), stage, age, gender, number of metastatic sites, weight loss and biochemical variables, such as serum albumin, sodium, alkaline phosphatase, lactat dehidrogenase levels are used to define prognosis in SCLC. However investigations are going on for finding a beter prognostic marker. The C-kit protein, which has type 3 receptor tyrosine kinase activity has been implicated in the pathophysiology of many tumors, including SCLC. Vascular endothelial growth factor (VEGF) expression was also corrolated to an increased risk of metastatic disease and a worse survival due to the role of angiogenesis in SCLC.

METHODS: In our study we aimed to evaluate VEGF and C-kit expression and relation between survival and clinical factors affecting the prognosis of 53 patients who were diagnosed with SCLC between January 2005- August 2010. The expressions of VEGF and C-kit were studied immonuhistochemically.

RESULTS: The expression of VEGF was detected in 64,2% and the expression of C-kit was detected in 60,4% of the patients.The results showed that VEGF and C-kit expressions were not associated with prognostic factors and survival. A multivariate analysis was perfomed to evaluate independent prognostic role of age, weight loss, PS, serum albumin level and stage. This analysis indicated that PS (p=0.001) and serum albumin (p=0.032) level had independent prognostic value on overall survival.

CONCLUSIONS: Although our results did not show any correlations we recommend that the prognostic value of VEGF and C-kit expressions, must be further investigated in prospective and large studies due to their role in pathogenesis.

CLINICAL IMPLICATIONS: The role of VEGF and C-kit expressions as an important event in the pathogenesis of SCLC are still debated, and remain to be clarified whether this expressions are relevant for tumor growth and survival. Based on the available data reported in the literature, C-kit tyrosine kinase inhibitors and VEGF-targeting monoclonal antibody bevacizumab have substantial clinical benefits. As a result, to understand the prognostic value of VEGF and C-kit expressıons new studies and large series needed.

DISCLOSURE: The following authors have nothing to disclose: Gulen Topaloglu, Aydin Yilmaz, Funda Demirag, Yurdanur Erdogan, Sezgi Sahin Duyar, Ulkü Yilmaz

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543